Background: Non–vitamin K oral anticoagulants have become the standard therapy for
preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF) …

Background In patients with atrial fibrillation (AF) and normal or slightly impaired renal
function, the use of direct oral anticoagulants (DOACs) is preferable to vitamin K antagonists …

Abstract Background Direct factor Xa inhibitors have been extensively prescribed for
multiple indications; however, hemodialysis patients have been excluded from most of the …

Purpose Patients with atrial fibrillation (AF) and end-stage renal disease on chronic
hemodialysis are at risk for thromboembolic and bleeding events. We aimed to perform a …

Background The effectiveness and safety of direct oral anticoagulants (DOACs) in patients
with atrial fibrillation (AF) and advanced kidney disease (AKD) has not been fully …

In Asian patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) undergoing
dialysis, the use of direct oral anticoagulants (DOACs) remains debatable. From the national …

Цель. Сравнить эффективность и безопасность прямых пероральных антикоагулянтов
(ПОАК) с антагонистом витамина К (АВК) у пациентов с фибрилляцией предсердий …

Background: Apixaban has been increasingly utilized for various FDA-approved indications,
including stroke prevention and venous thromboembolism (VTE) treatment in patients with …

目的: 评估与维生素K 口服抗凝剂(VKA) 相比, 在心房颤动(房颤) 合并透析患者中使用利伐沙班
或阿哌沙班抗凝的有效性和安全性. 方法: 计算机检索PubMed, Embase, CochraneLibrary …

Aim. This study aims to compare efficacy and safety of direct oral anticoagulants (DOAC)
with vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and chronic kidney …